JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265947

Human CD58 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

CD58 KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon 1 and 2 bp deletion in exon 1. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.

View Alternative Names

AG3, CD58 antigen, CD58 antigen (lymphocyte function associated antigen 3)1, CD58 antigen, (lymphocyte function associated antigen 3), CD58 molecule, FLJ23181, FLJ43722, LFA3_HUMAN, Lymphocyte Function Associated Antigen Type 3, Lymphocyte function-associated antigen 3, Surface glycoprotein LFA-3

4 Images
Western blot - Human CD58 knockout HeLa cell line (AB265947)
  • WB

Lab

Western blot - Human CD58 knockout HeLa cell line (AB265947)

False colour image of Western blot : Anti-CD58 antibody [EPR24012-147] staining at 1/1000 dilution shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution shown in red. In Western blot ab275392 was shown to bind specifically to CD58. A band was observed at 55 kDa in wild-type HeLa cell lysates with no signal observed at this size in CD58 knockout cell line ab265947 (knockout cell lysate ab257880). To generate this image wild-type and CD58 knockout HeLa cell lysates were analysed. First samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °. Blots were washed four times in TBS-T incubated with secondary antibodies for 1 h at room temperature washed again four times then imaged.Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.

All lanes:

Western blot - Anti-CD58 antibody [EPR24012-147] (<a href='/en-us/products/primary-antibodies/cd58-antibody-epr24012-147-ab275392'>ab275392</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

CD58 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human CD58 knockout HeLa cell lysate (<a href='/en-us/products/cell-lysates/human-cd58-knockout-hela-cell-lysate-ab257880'>ab257880</a>)

Lane 2:

Western blot - Human CD58 knockout HeLa cell line (ab265947)

Lane 3:

Raji cell lysate at 20 µg

Lane 4:

SH-SY5Y cell lysate at 20 µg

Predicted band size: 28 kDa

Observed band size: 55 kDa

false

Western blot - Human CD58 knockout HeLa cell line (AB265947)
  • WB

Lab

Western blot - Human CD58 knockout HeLa cell line (AB265947)

Lanes 1-4 : Merged signal (red and green). Green - ab196648 observed at 43 kDa. Red - loading control ab8245 observed at 37 kDa.

ab196648 Anti-CD58 antibody [EP15041] was shown to specifically react with CD58 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab265947 (knockout cell lysate ab257880) was used. Wild-type and CD58 knockout samples were subjected to SDS-PAGE. ab196648 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4° at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-CD58 antibody [EP15041] (<a href='/en-us/products/primary-antibodies/cd58-antibody-ep15041-ab196648'>ab196648</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

CD58 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human CD58 knockout HeLa cell line (ab265947)

Lane 3:

HAP1 cell lysate at 20 µg

Lane 4:

Daudi cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/20000 dilution

Predicted band size: 28 kDa

Observed band size: 43 kDa

false

Sanger Sequencing - Human CD58 knockout HeLa cell line (AB265947)
  • Sanger seq

Unknown

Sanger Sequencing - Human CD58 knockout HeLa cell line (AB265947)

Allele-1 : 11 bp deletion in exon 1.

Sanger Sequencing - Human CD58 knockout HeLa cell line (AB265947)
  • Sanger seq

Unknown

Sanger Sequencing - Human CD58 knockout HeLa cell line (AB265947)

Allele-2 : 2 bp deletion in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon 1 and 2 bp deletion in exon 1

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265947-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265947-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265947 Human CD58 knockout HeLa cell line", "number":"AB265947-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265947-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265947 Human CD58 knockout HeLa cell line", "number":"AB265947-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265947-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265947-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265947 Human CD58 knockout HeLa cell line", "number":"AB265947-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265947-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265947 Human CD58 knockout HeLa cell line", "number":"AB265947-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
CD58
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CD58 also known as lymphocyte function-associated antigen 3 (LFA-3) is a glycoprotein with a molecular mass of approximately 60 kDa. It is present on the surface of various cell types including antigen-presenting cells epithelial cells and some other leukocytes. This protein serves as a ligand for CD2 which is expressed on T cells and natural killer cells. Through its interaction with CD2 CD58 mediates cell adhesion and plays a role in immunological synapse formation which is essential for effective immune responses.
Biological function summary

Lymphocyte function-associated antigen 3 acts as a significant participant in the immune system. It plays a role in T cell activation and facilitates interactions between T cells and antigen-presenting cells. CD58 forms part of a complex network of cell surface proteins that enhances immune surveillance and response. Its role highlights its importance in adaptive immunity by promoting cell-to-cell communication and activation.

Pathways

CD58 participates in the cell adhesion pathways. It interacts closely with CD2 which is involved in the activation and signaling of T cells. Through this interaction CD58 plays roles in pathways like T cell receptor signaling and immune response. It enhances cell-cell adhesion helping T cells maintain their position during immune surveillance and activation.

CD58 relates to conditions such as autoimmune diseases and certain cancers. In autoimmune disorders aberrant expression or function of CD58 may contribute to inappropriate immune activation leading to tissue damage. In cancer CD58 alterations can affect tumor immune evasion influencing how the immune system recognizes and attacks cancer cells. In multiple sclerosis an autoimmune disease the interaction between CD58 and CD2 has been studied providing insights into its role in disease mechanisms.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com